An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Harrow Health to Present at Aegis Virtual Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Harrow Health, Inc. (NASDAQ: HROW), a healthcare company focused on ophthalmology, announced that CEO Mark L. Baum and CFO Andrew Boll will present at the Aegis Capital Corp. Virtual Conference from February 23-25, 2022. Their presentation is scheduled for February 24, 2022, at 3:30 p.m. ET. To view the presentation, attendees can access the link on Harrow Health's website in the events section. Harrow Health operates ImprimisRx and Visionology, and holds equity positions in Eton Pharmaceuticals, Surface Ophthalmics, and Melt Pharmaceuticals.
Positive
None.
Negative
None.
NASHVILLE, Tenn.--(BUSINESS WIRE)--
Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic-focused healthcare company, today announced that Mark L. Baum, Chief Executive Officer, and Andrew Boll, Chief Financial Officer, will present a company overview at the Aegis Capital Corp.Virtual Conference to be held on February 23-25, 2022.
To access Harrow Health’s presentation, which will begin on Thursday, February 24, 2022, at 3:30 p.m. ET/2:30 p.m. CT, please click on the link to the Aegis conference on the events section of Harrow Health’s website.
About Harrow Health
Harrow Health, Inc. (NASDAQ: HROW) is an ophthalmic-focused healthcare company. The Company owns and operates ImprimisRx, one of the nation’s leading ophthalmology-focused pharmaceutical businesses, and Visionology, a direct-to-consumer eye care subsidiary focused on chronic vision care. Harrow Health also holds non-controlling equity positions in Eton Pharmaceuticals, Surface Ophthalmics and Melt Pharmaceuticals, all of which started as Harrow Health subsidiaries, and owns royalty rights in four clinical‑stage drug candidates being developed by Surface Ophthalmics and Melt Pharmaceuticals. For more information about Harrow Health, please visit the Investors section of the corporate website, harrowinc.com.
